Features of management of a patient with secondary progressive multiple sclerosis: a clinical case

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Timely diagnosis of the transition from relapsing-remitting multiple sclerosis (MS) to secondary progressive multiple sclerosis (SPMS) is extremely difficult due to the lack of clear criteria characterizing this period of the disease. The choice of therapeutic strategies in this case is a difficult task, and is associated by additional difficulties in the treatment of patients with low treatment adherence.

Description of a clinical case. A clinical case illustrating the difficulty in determining the type of MS is presented for consideration. The questions had to be resolved: remitting or secondary progressive course of the disease and, if SPMS, then with or without exacerbations? A patient who had suffered from MS for 18 years showed an increase in neurological symptoms over 1.5 years by 1 point on the EDSS scale, and an increase in the number of lesions in an MRI study. However, there were certain difficulties in interpreting these changes: they occurred as a result of exacerbation or progression of the disease. A comprehensive assessment of the data, based on current clinical guidelines and modern ideas about the management of MS patients, made it possible to select the optimal treatment strategy for MS patients with low treatment adherence.

Conclusion. A thorough analysis of the available clinical and radiological data of patients with MS, an attentive, trusting relationship between the attending physician and the patient, and the involvement of the patient and his relatives in discussing the choice of therapy are an important component in the practice of a neurologist. Wide therapeutic options and the emergence of innovative drugs contribute to a patient-centered approach to the treatment of MS.

Full Text

Restricted Access

About the authors

G. N. Belskaya

Scientific Center for Neurology

Author for correspondence.
Email: belskaya@neurology.ru
ORCID iD: 0000-0001-9831-8970

Dr. Sci. (Med.), Professor, Head of the Multidisciplinary Clinical Diagnostic Center, Scientific Center of Neurology

Russian Federation, Moscow

I. G. Lukashevich

City Clinical Hospital No. 1

Email: belskaya@neurology.ru
ORCID iD: 0000-0003-0237-8624
Russian Federation, Chelyabinsk

References

  1. Время диктует: Кайендра – таргетная терапия вторично-прогрессирующего рассеянного склероза. Эффективная фармакотерапия. 2021;17(34):28–33. [Time dictates: Kayendra is a targeted therapy for secondary progressive multiple sclerosis. Effective pharmacotherapy. 2021;17(34):28–33. (In Russ.)].
  2. Lublin F.D., Reingold S.C., Cohen J.A., et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86. doi: 10.1212/WNL.0000000000000560.
  3. Sabsabi S., Mikhael E., Jalkh G., et al. Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence. Patient Preference and Adherence. 2022;16:1307–19. doi: 10.2147/PPA.S221882.
  4. Thompson A.J., Baranzini S.E., Geurts J., et al. Multiple sclerosis. Lancet. 2018;391(10130):1622–36. doi: 10.1016/S0140-6736(18)30481-1.
  5. Cree B.A.C., Gourraud P.A., Oksenberg J.R., et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80 (4):499–510. doi: 10.1002/ana.24747.
  6. Евдошенко Е.П., Неофидов Н.А., Бахтиярова К.З. и др. Эффективность и безопасность сипонимода у пациентов с вторично-прогрессирующим рассеянным склерозом в российской популяции. Журн. неврологии и психиатрии им. С.С. Корсакова. 2019;119(10, вып.2):110–19. [Evdoshenko E.P., Neofidov N.A., Bakhtiyarova K.Z., et al. Efficacy and safety of ciponimod in patients with secondary progressive multiple sclerosis in the Russian population. J. Neurol. Psych. named after S.S. Korsakov. 2019;119(10, issue 2):110–19. (In Russ.)]. doi: 10.17116/jnevro2019119102110.
  7. Kołtuniuk A., Chojdak-Łukasiewicz J. Adherence to Therapy in Patients with Multiple Sclerosis-Review. Int J Environ Res Public Health. 2022;19(4):2203. doi: 10.3390/ijerph19042203.
  8. Хачанова Н.В., Бойко А.Н., Бахтиярова К.З., и др. Рекомендации экспертного совещания «Вторично-прогрессирующий рассеянный склероз: нерешенные вопросы и перспективы». Неврология, нейропсихиатрия, психосоматика. 2019;11(4):172–75. [Khachanova N.V., Boyko A.N., Bakhtiyarova K.Z., et al. Recommendations of the expert meeting «Secondary progressive multiple sclerosis: unresolved issues and prospects». Neurol Neuropsych Psychosomat. 2019;11(4):172–75. (In Russ.)].
  9. Katz Sand I., Krieger S., Farrell C., et al. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler. 2014;20(12):1654–57. doi: 10.1177/1352458514521517.
  10. Касаткин Д.С., Хачанова Н.В., Алифирова В.М., и др. Новые возможности терапии у пациентов с вторично-прогрессирующим рассеянным склерозом препаратом сипонимод. Неврология, нейропсихиатрия, психосоматика. 2021;13(1):138–44. [Kasatkin D.S., Khachanova N.V., Alifirova V.M., et al. New possibilities of therapy in patients with secondary progressive multiple sclerosis with the drug ciponimod. Neurol Neuropsych Psychosomat. 2021;13(1):138–44. (In Russ.)]. doi: 10.14412/2074-2711-2021-1-138-144.
  11. Deibel F., Edwards M., Edwards A. Patients, carers and providers experiences and requirements for support in self-management of multiple sclerosis: a qualitative study. Eur J Pers Cent Healthc. 2013;1(2):457. doi: 10.5750/ejpch.v1i2.687.
  12. Клинические рекомендации. Рассеянный склероз. 2022. ID:739. [Clinical recommendations. Multiple sclerosis. 2022. ID:739. (In Russ.)]. URL: https://cr.minzdrav.gov.ru/recomend/739_1
  13. Kappos L., Bar-Or A., Cree B.A.C., et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind randomised, phase 3 study. Lancet. 2018;391(10127):1263–73. doi: 10.1016/S0140-6736(18)30475-6.
  14. Evans C., Marrie R.A., Yao S., et al. Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study. BMJ. Open. 2021;11(2):e043930. doi: 10.1136/bmjopen-2020-043930.
  15. Burkhard A., Toliver J., Rascati K. Association between multiple sclerosis disease severity and adherence to disease-modifying therapies. J Manag Care Spec Pharm. 2021;27:915–23. doi: 10.18553/jmcp.2021.27.7.915.
  16. Menzin J., Caon C., Nichols C., et al. Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple Sclerosis. J Manag Care Pharm. 2013;19:S24–40. doi: 10.18553/jmcp.2013.19.s1.S24.
  17. Di Battista G., Bertolotto A., Gasperini C., et al. Multiple Sclerosis State of the Art (SMART): A Qualitative and Quantitative Analysis of Therapy’s Adherence, Hospital Reliability’s Perception, and Services Provided Quality. Mult. Scler. Int. 2014;752318. doi: 10.1155/2014/ 752318.
  18. Jonker M.F., Donkers B., Goossens L.M.A., et al. Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options. Med Decis Mak. 2020;40(2):198–211. doi: 10.1177/0272989X19897944.
  19. Garcia-Dominguez J.M., Munoz D., Comellas M., et al. Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment. Patient Prefer Adherence. 2016;10:1945–56. doi: 10.2147/PPA.S114619.
  20. Bauer B., Brockmeier B., Devonshire V., et al. An international discrete choice experiment assessing patients’ preferences for disease-modifying therapy attributes in multiple sclerosis. Neurodegener Dis Manag. 2020;10(6):369–82. doi: 10.2217/nmt2020-0034.
  21. Col N.F., Solomon A.J., Springmann V., et al. Whose preferences matter? A patient-centered approach for eliciting treatment goals. Med. Decis. Mak. 2018;38(1):44–55. doi: 10.1177/0272989X17724434.
  22. Bottomley C., Lloyd A., Bennett G., Adlard N. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in multiple sclerosis. J Med Econ. 2017;20(8):863–70. doi: 10.1080/13696998.2017.1336099.
  23. Remington G., Rodriguez Y., Logan D., et al. Facilitating Medication Adherence in Patients with Multiple Sclerosis. Int J MS Care. 2013;15:36–45. doi: 10.7224/1537-2073.2011-038.
  24. Erbay O., Usta Yeshilbalkan O., Yuceyar N. Factors Affecting the Adherence to Disease-Modifying Therapy in Patients with Multiple Sclerosis. J Neurosci Nurs. 2018;50:291–97. doi: 10.1097/JNN.0000000000000395.
  25. Devonshire V., Lapierre Y., Macdonell R., et al. The Global Adherence Project (GAP): A multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: Global Adherence Project: Adherence to DMTs in MS. Eur J Neurol. 2011;18:69–77. doi: 10.1111/j.1468-1331.2010.03110.x.
  26. Koskderelioglu A., Gedizlioglu M., Ortan P., Ocek O. Evaluation of the Adherence to Immunmodulatory Treatment in Patients with Multiple Sclerosis. Arch. Neuropsych. 2015;52:376–79. doi: 10.5152/npa.2015.8825.
  27. Bar-Or A., Weinstock-Guttman B., Mao-Draayer Y., et al. Safety and Tolerability of Conversion to Siponimod With and Without Titration in Patients with Advancing Forms of RMS: Interim Results of the Phase 3b EXCHANGE Study. Poster Presentation at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 2021. URL: https://www.medcommshydhosting.com/MSKnowledgecenter/ectrims/2021/posters/P672_ECTRIMS2021.pdf.
  28. Boyko A., Therapontos C., Horakova D., et al. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals. Mult Scler Relat Disord. 2021;50:102778. doi: 10.1016/j.msard.2021.102778.
  29. Вольская Е.А. Пациентский комплаенс. Обзор тенденций в исследованиях. Ремедиум. 2013(11):6-15. [Volskaya E.A. Patient compliance. An overview of research trends. A remedy. 2013(11):6–15. (In Russ.)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies